Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Zephyr Energy, Quantum Blockchain, Pathos Communications, AOTI, Scancell - Small Cap Snapshot

Zephyr Energy, Quantum Blockchain, Pathos Communications, AOTI, Scancell - Small Cap Snapshot

Zephyr Energy PLC (AIM:ZPHR, OTCQB:ZPHRF, FRA:VD5N) has lined up non-dilutive financing of up to $15 million for its Paradox Basin project in Utah, with Atlas Oil Company set to be repaid purely from future production. No shares will be issued and no working interest will be sold. Watch more

Quantum Blockchain Technologies PLC (AIM:QBT, FRA:BYA1) has received US approval for a patent application covering technology designed to cut redundant calculations in Bitcoin mining hardware. The company says it will now explore licensing deals with established ASIC manufacturers. Read more

Pathos Communications Plc (LSE:NEWS) expects first-half revenue to jump 14% to $7.3 million, with adjusted EBITDA up 31%, as its AI platform and new sales structure start to deliver. Monthly client sign-ups are up around 30% and repeat customers have more than doubled. Read more

AOTI Inc (AIM:AOTI) says underlying first-half revenue grew 18%, ahead of its full-year guidance, with Veterans Administration demand bouncing back strongly. Proposed nationwide Medicare coverage for its wound-care technology could be transformative once finalised. Read more

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP) has confirmed its UK fundraise raised £15.7 million, with the retail offer upsized after strong demand. The money will help fund a global phase III trial of its melanoma treatment alongside its merger with US biotech Neuphoria. Read more

Follow us and subscribe on YouTube, our social channels, and on proactiveinvestors.co.uk.

Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK